Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01390337 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01390337 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 19 participants.
The verdict
NCT01390337, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to define the maximum tolerated dose (MTD) of AC220 when combined with induction and consolidation therapy and as maintenance therapy following induction and consolidation.
Interventions
- DRUG cytarabine
- DRUG daunorubicin
- DRUG AC220
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01390337
The ClinicalTrials.gov registry entry for NCT01390337 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cytarabine is the first listed.
NCT01390337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01390337 about?
NCT01390337 is a clinical study titled "A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)". The purpose of this study is to define the maximum tolerated dose (MTD) of AC220 when combined with induction and consolidation therapy and as maintenance therapy following induction and consolidation.
What is the current status of trial NCT01390337?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2011-10. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01390337?
The interventions under investigation include: cytarabine (DRUG), daunorubicin (DRUG), AC220 (DRUG).
Who is sponsoring clinical trial NCT01390337?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.